Price Alert

Travere Therapeutics Inc. (TVTX)

NASDAQ: TVTX · Real-Time Price · USD

18.41

0.18 (0.99%)

At close: Aug 15, 2025, 10:19 AM

0.99% (1D)

Bid	18.36
Market Cap	1.64B
Revenue (ttm)	333.87M
Net Income (ttm)	-169.06M
EPS (ttm)	-2.02
PE Ratio (ttm)	-9.11
Forward PE	29.71
Analyst	Buy

Ask	18.43
Volume	294,670
Avg. Volume (20D)	1,745,654
Open	18.33
Previous Close	18.23
Day's Range	18.12 - 18.54
52-Week Range	8.46 - 25.29
Beta	0.75

About TVTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TVTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TVTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Travere Therapeutics has released their quartely earnings on Aug 6, 2025:

Revenue of $114.4M exceeds estimates by $15.32M, with 119.26% YoY growth.

EPS of 0.13 exceeds estimates by 0.41, with 120.00% YoY growth.

Next Earnings Release

Travere Therapeutics Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-20.57%

Travere Therapeutics shares are trading lower. The... Unlock content with Pro Subscription

3 months ago

+0.28%

Travere Therapeutics shares are trading lower. The company announced that the FDA accepted its supplemental New Drug Application for traditional approval of FILSPARI for the treatment of focal segmental glomerulosclerosis.

News

2 days ago · seekingalpha.com

Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore

Travere Therapeutics has successfully executed a significant restructuring to recover from previous setbacks and improve its financial health. It has built a compact pipeline of kidney therapy drugs w...

3 days ago · businesswire.com

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to ...

1 week ago · seekingalpha.com

Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Christopher Cline - Chief Financial Officer Eric M. Dube - President, CEO & Di...

1 week ago · zacks.com

Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street e...

1 week ago · zacks.com

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.9 per share a year ago.

1 week ago · businesswire.com

Travere Therapeutics Reports Second Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its second quarter 2025 financial results and provided a corporate update. “We continue to make strong progress ag...

1 week ago · businesswire.com

Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity 45th An...

2 weeks ago · businesswire.com

Travere Therapeutics to Report Second Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. fin...

2 months ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors a...

2 months ago · businesswire.com

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference.

Load More News